Lund, Sweden, 2012-01-10 10:24 CET (GLOBE NEWSWIRE) --
In the end of 2011 FUJIFILM RI Pharma Co Ltd held a seminar for over 200 Japanese doctors with the focus on Bonenavi (the Japanese verison of EXINI bone). Presentations were made by several eminent doctors within the Japanese expertise of radiology and by Swedish Professor, Lars Edenbrandt.
During the seminar for Japanese doctors in radiology and nuclear medicine, Chairperson and Professor Ken Nakajima of Nuclear Medicine at Kanazawa University announced that Bonenavi was one of the most interesting developments within the Japanese nuclear medicine market in several years. The following presentations where all positive to Bonenavi.
Following presentations where made during the seminar:
- ”Data Analysis using Bonenavi”, Chiba Cancer Center, Dr. Ichihara
- “Features and Development”, Gunma Cancer Center, Dr. Horikoshi
- “Diagnosis Experience”, Kanazawa University, Dr. Wakabayashi
- “Evaluation of Treatment Effect in Prostate Cancer”, Shimane University, Dr. Arike
- “Diagnosis of Prostate Cancer”, Tokyo Medical School, Dr. Yoshimura
- “Evaluation of Treatment Effect in Breast Cancer”, Saitama Cancer Center, Dr. Inoue
- “Development of Bonenavi and Clinical Use”, EXINI Diagnostics AB, Professor Edenbrandt
General Manager, Marketing at FUJIFILM RI Pharma, Toshiya Morita:
"This product has given us easier access to our customer and also improved our reputation in the Japanese medical community."
For more information, please contact:
Magnus Aurell, CEO
Phone: +46 46-286 54 25
E-mail: magnus.aurell@exini.com
About EXINI Diagnostics AB (publ)
EXINI Diagnostics AB (publ) offers advanced solutions for medical decision support to hospitals worldwide. The system is based on advanced image analysis by artificial intelligence and can make its own interpretation of radiology images and provide diagnostic suggestions. In this way the system is used as a decision support for the diagnosing doctor. EXINI is working with products for the diagnosis of some of the most frequent endemic diseases such as coronary heart disease, cancer, dementia and Parkinson's disease. The company was founded in 1999 by Professor Lars Edenbrandt. EXINI is listed on the stock market NASDAQ OMX First North and has about 400 shareholders. Principal owner is Bo Håkansson. Thenberg & Kinde Fondkomission AB acts as Certified Adviser.
|
EXINI Diagnostics AB, Ideon Science Park, Scheelevägen 19A, SE-223 70 Lund, Sweden Phone: +46 46 286 54 20, Fax: +46 46 286 54 29, info@exini.com, www.exini.com, VAT-no: SE556576199501 |
